<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01607658</url>
  </required_header>
  <id_info>
    <org_study_id>TBS-2-AMB-2012-01</org_study_id>
    <nct_id>NCT01607658</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder</brief_title>
  <official_title>A Placebo-Controlled, Randomized, Double-Blind, Parallel-Group, Dose-Finding Trial to Evaluate the Efficacy and Safety of TBS-2 Intranasal Testosterone Gel in Women With Acquired Female Orgasmic Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerus Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acerus Pharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess and compare the effects of 3 dose strengths of TBS-2
      intranasal testosterone gel to placebo on the occurrence of orgasm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Orgasms Over an 84 Day Period Compared to Placebo Over the Entire Treatment Period</measure>
    <time_frame>84 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Sexual Event Satisfaction Over a 28-day Period (Day 57 to Day 84) Compared to Baseline (Day -28 to Day 0)</measure>
    <time_frame>Baseline (Day -28 to Day 0) and End of Study (Day 57 to 84)</time_frame>
    <description>as measured by Monash Women's Health Program Female Sexual Satisfaction Questionnaire (MONASH WHP FSSQ) question 11.
MONASH WHP FSSQ question 11 asks participants to comment on how satisfying they found the sex to be from &quot;Not at all&quot; to &quot;Very much so&quot;. The lowest score is 1 and the highest is 9. All scores for each 28-day period were averaged. Change from baseline was obtained by subtracting baseline 28-day average from the 28-day period at the end of the study (Day 57 to 84).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Distress Due to Female Orgasmic Disorder From Day 0 Baseline to Day 84</measure>
    <time_frame>Day 0 and Day 84</time_frame>
    <description>as measured by Female Sexual Distress Scale (FSDS-DAO) Question #15 on Day 0 and 84, respectively. Question #15 evaluates the level of distress related to problems with orgasm. It is rated on a 5-point Likert scale (from 0 to 4, i.e. never [0], rarely [1], occasionally [2], frequently [3], or always [4]). Higher scores indicate more distress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global Sexual Functioning From Day 0 to Day 84</measure>
    <time_frame>Day 0 and Day 84</time_frame>
    <description>as measured by Female Sexual Function Index (FSFI) on Day 0 and 84, respectively. The FSFI, a 19-item questionnaire, has been developed as a brief, multidimensional self-report instrument for assessing the key dimensions of sexual frustration in women. The questionnaire provides scores on 6 domains of sexual function (desire, arousal, lubrication, orgasm, satisfaction, and pain) as well as a total score. Fifteen items are rated on a 6-point Likert scale (from 0 to 5) and 4 items on a 5-point Likert scale (from 1 to 5). The scores are added and converted using a conversion factor so that the maximum score for each domain is 6. The overall FSFI score can range from 2 to 36. Higher scores indicate better or higher sexual function.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">253</enrollment>
  <condition>Female Orgasmic Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo intranasal gel administered prn, 2-8 hours before a planned sexual event</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose TBS-2</intervention_name>
    <description>Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
    <arm_group_label>Experimental 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medium dose TBS-2</intervention_name>
    <description>Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
    <arm_group_label>Experimental 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose TBS-2</intervention_name>
    <description>High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
    <arm_group_label>Experimental 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Subjects who meet the following criteria may be included in the study:

        At Visit 1:≤

          -  Be a generally healthy female aged 18 years and older, inclusive, who has no physical
             impediment to sexual function

          -  Have a diagnosis of acquired female orgasmic disorder defined as absence of orgasm
             during the past 6 months and according to the Diagnostic and Statistical Manual of
             Mental Disorders IV (DSM-IV) criteria. Subtype should be generalized and not due to
             etiological factors that would be unlikely to be related to hormone function (eg,
             depression, relationship discord, alcoholism, surgery, injury). Hypoactive sexual
             desire disorder as a co-morbid disorder is allowed only if it began after the female
             orgasmic disorder diagnosis;

          -  Have a score of &gt;15 with a score of ≥2 for question #15 on the FSDS DAO at Screening
             Visit;

          -  Be a sexually active, hetero- or homosexual woman in a steady relationship for at
             least 6 months and agree to have at least 4 sexual events over 28-day period of time.
             The subject's partner should not have any untreated sexual dysfunctions;

          -  Be on a reliable birth control method (ie, stable systemic hormonal contraception for
             the whole duration of the study and 30 days after study completion [for at least 3
             months prior to study], IUD, barrier method) or not engaging in heterosexual
             intercourse. Birth control method used by subject at screening is not to be changed
             during the course of the study;

          -  Have a normal ENT examination;

          -  Have a body mass index ≤35;

          -  Have a clinically acceptable pelvic examination and Pap smear as read by a licensed
             laboratory facility (no evidence of malignancy) within the 2 years prior to
             Randomization;

          -  Have a clinically acceptable mammogram;

          -  Be able to complete a web-based questionnaire within 24 hours of each sexual event;

          -  Be able to read English and provide written informed consent; and

        At Visit 2:

          -  Have at least 4 sexual events and an absence of orgasm during the 28 day
             Screening/Baseline Period as determined by MONASH WHP FSSQ.

        Exclusion Criteria

        Subjects who meet any of the following criteria will not be eligible to participate in the
        study:

          -  Have a known history of hypersensitivity to testosterone or any component of the study
             drug;

          -  Have a history of any clinically relevant psychiatric disorder that could impact
             sexual functioning, contribute to increased risk for patient safety, or significantly
             compromise participation in the study (eg, bipolar disorders, psychotic disorders,
             severe anxiety, eating disorders, borderline personality disorder, untreated Major
             Depressive Disorder);

          -  Have a score of ≥14 on the Beck Depression Inventory II at Screening Visit. Subjects
             with a score of ≥14 and ≤19 at Screening may be eligible to participate in the study
             if a specialist (psychologist or psychiatrist) concludes that the subject is not
             clinically depressed;

          -  Have other concurrent female sexual dysfunction disorders as defined by DSM-IV
             criteria, eg, Sexual Aversion Disorder, Substance-Induced sexual dysfunction,
             dyspareunia (not caused by inadequate foreplay stimulation or alleviated by
             lubricants), vaginismus, Gender Identity Disorder, paraphilia, or sexual dysfunction
             due to a general medical condition;

          -  Be experiencing relational discord;

          -  Have a history of dementia or other neurodegenerative diseases, organic brain disease,
             stroke, transient ischemic attacks, brain surgery, significant brain trauma, multiple
             sclerosis, spinal cord injury, peripheral neuropathy, and epilepsy (febrile seizures
             limited to childhood do not exclude patients);

          -  Be currently receiving treatment with selective norepinephrine reuptake inhibitors
             (SNRIs) and selective serotonin reuptake inhibitors (SSRIs) and/or medications that
             interfere with the metabolism of testosterone (eg, anastrozole, clomiphene,
             testolactone, ketoconazole, spironolactone, histamine 2 [H2 receptor blockers, etc.]);

          -  Have a history of, or current evidence of, abuse of alcohol or any drug substance,
             licit or illicit, or be a regular drinker of more than 3 units of alcohol daily (1
             unit = 300 mL beer, 1 glass wine, 1 measure spirit);

          -  Have a history of cancer other than nonmelanotic skin cancer;

          -  Have a history of deep venous thrombosis or coagulation disorders;

          -  Have a significant medical condition (eg, hepatic, renal cardiovascular, endocrine
             including diabetes mellitus). Subjects with treated hypertension, treated
             hyperlipidemia, or treated thyroid disease will not be excluded provided they have
             been on stable therapy for at least 3 months;

          -  Had any major surgical procedure within the past 6 months including hysterectomy,
             hysterectomy with bilateral salpingo oophorectomy, or vaginal incontinence surgery

          -  Are receiving treatment with systemic glucocorticosteroids, sex steroid hormones such
             as androgens (eg, dehydroepiandrosterone [DHEA]) or gestagens (eg, anabolic steroids)
             and using any post menopausal hormone therapy;

          -  Have a history of severe or multiple drug allergies, severe adverse drug reaction or
             drug-related leucopenia;

          -  Have a history of nasal disorders (eg, atrophic rhinitis, polyposis, abuse of nasal
             decongestants, clinically relevant nasal septum deviation, recurrent epistaxis), sinus
             disease or nasal surgery and/or seasonal or perennial allergic rhinitis in the active
             phase;

          -  Be using any form of chronic intranasal medication delivery, specifically nasal
             corticosteroids or decongestants;

          -  Have a diagnosis of sleep apnea and be using a continuous positive airway
             pressure/automatic positive airway device;

          -  Have a history of diagnosed hirsutism, alopecia or clinically significant acne;

          -  Have a history of diagnosed polycystic ovarian syndrome;

          -  Have pelvic inflammatory disease, chronic urinary tract, vaginal, or cervical
             infections, interstitial cystitis, vulvodynia, or significant symptomatic vaginal
             atrophy;

          -  Are currently pregnant, by history or positive serum pregnancy test at Screening Visit
             or have been pregnant within the 12 months prior to Screening Visit;

          -  Is breast feeding or have breast fed within the 6 months prior to Screening Visit;

          -  Are positive for hepatitis B-surface antigen, hepatitis C, or Human Immunodeficiency
             Virus (HIV);

          -  Have abnormal thyroid stimulating hormone level;

          -  For pre-menopausal women, have SHBG value &lt;18 86 nmol/L; For post-menopausal women,
             have SHBG value &gt;160 nmol/L

          -  Have any medical or psychiatric condition, physical examination finding, or laboratory
             result which, in the opinion of the principal investigator, would put the subject at
             additional medical risk or make her unlikely to be able to comply with study
             requirements; or

          -  Have received any drug as part of a research study within 30 days prior to the
             Screening Visit.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalia Tkachenko, MD</last_name>
    <role>Study Director</role>
    <affiliation>Trimel Pharmaceuticals Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Affiliated Research Center Inc.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality of Life Medical Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Sexual Medicine</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Women's Health Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thameside OB/GYN Centre</name>
      <address>
        <city>Groton</city>
        <state>Connecticut</state>
        <zip>06340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Hartford Women's Health Associates</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Physiology Associates</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research East LLC</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Marital and Sexual Health of South Florida</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta North Gynecology, PC</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Practice</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Reseach</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Center for Sexual Health</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QUEST Research Institute</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <zip>48025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Health Research Institute</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Womens Clinic of Lincoln P.C.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University School of Nursing</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lillestol Research LLC</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Marital and Sexual Health Inc.</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Center for Women's Health Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Urogynecology Associates (TRIHEALTH)</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Philadelphia LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates, Inc</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes and Endocrinology</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Psychiatric Research Center Dba Croft Group Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Center for Psychiatric Clinical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Research Center</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tidewater Physicians for Women</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Clincial Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash University</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keogh Institute for Medical Research</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Robinson Institute University of Adelaide</name>
      <address>
        <city>North Adelaide</city>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Gross Research Unit</name>
      <address>
        <city>Randwick</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Clinical Research Inc.</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5A 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gain Medical Centre</name>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3K 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery Clinical Services, Ltd</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Clinical Research Inc</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3N7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 18, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2012</study_first_posted>
  <results_first_submitted>March 28, 2018</results_first_submitted>
  <results_first_submitted_qc>August 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2018</results_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
Placebo: placebo intranasal gel administered prn, 2-8 hours before a planned sexual event</description>
        </group>
        <group group_id="P2">
          <title>Low Dose TBS-2</title>
          <description>Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
Low dose TBS-2: Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
        </group>
        <group group_id="P3">
          <title>Medium Dose TBS-2</title>
          <description>Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
Medium dose TBS-2: Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
        </group>
        <group group_id="P4">
          <title>High Dose TBS-2</title>
          <description>High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
High dose TBS-2: High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
Placebo: placebo intranasal gel administered prn, 2-8 hours before a planned sexual event</description>
        </group>
        <group group_id="B2">
          <title>Low Dose TBS-2</title>
          <description>Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
Low dose TBS-2: Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
        </group>
        <group group_id="B3">
          <title>Medium Dose TBS-2</title>
          <description>Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
Medium dose TBS-2: Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
        </group>
        <group group_id="B4">
          <title>High Dose TBS-2</title>
          <description>High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
High dose TBS-2: High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="58"/>
            <count group_id="B4" value="63"/>
            <count group_id="B5" value="253"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.4" spread="12.36"/>
                    <measurement group_id="B2" value="44.5" spread="12.09"/>
                    <measurement group_id="B3" value="44.3" spread="11.64"/>
                    <measurement group_id="B4" value="42.4" spread="11.47"/>
                    <measurement group_id="B5" value="43.4" spread="11.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="253"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="191"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Orgasms Over an 84 Day Period Compared to Placebo Over the Entire Treatment Period</title>
        <time_frame>84 days</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
Placebo: placebo intranasal gel administered prn, 2-8 hours before a planned sexual event</description>
          </group>
          <group group_id="O2">
            <title>Low Dose TBS-2</title>
            <description>Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
Low dose TBS-2: Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
          </group>
          <group group_id="O3">
            <title>Medium Dose TBS-2</title>
            <description>Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
Medium dose TBS-2: Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
          </group>
          <group group_id="O4">
            <title>High Dose TBS-2</title>
            <description>High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
High dose TBS-2: High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Orgasms Over an 84 Day Period Compared to Placebo Over the Entire Treatment Period</title>
          <population>ITT Population</population>
          <units>orgasms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="4.60"/>
                    <measurement group_id="O2" value="3.9" spread="5.22"/>
                    <measurement group_id="O3" value="3.2" spread="4.70"/>
                    <measurement group_id="O4" value="1.9" spread="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sexual Event Satisfaction Over a 28-day Period (Day 57 to Day 84) Compared to Baseline (Day -28 to Day 0)</title>
        <description>as measured by Monash Women's Health Program Female Sexual Satisfaction Questionnaire (MONASH WHP FSSQ) question 11.
MONASH WHP FSSQ question 11 asks participants to comment on how satisfying they found the sex to be from &quot;Not at all&quot; to &quot;Very much so&quot;. The lowest score is 1 and the highest is 9. All scores for each 28-day period were averaged. Change from baseline was obtained by subtracting baseline 28-day average from the 28-day period at the end of the study (Day 57 to 84).</description>
        <time_frame>Baseline (Day -28 to Day 0) and End of Study (Day 57 to 84)</time_frame>
        <population>The number of participants analyzed is equal to the number of participants who completed the Day 84 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
Placebo: placebo intranasal gel administered prn, 2-8 hours before a planned sexual event</description>
          </group>
          <group group_id="O2">
            <title>Low Dose TBS-2</title>
            <description>Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
Low dose TBS-2: Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
          </group>
          <group group_id="O3">
            <title>Medium Dose TBS-2</title>
            <description>Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
Medium dose TBS-2: Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
          </group>
          <group group_id="O4">
            <title>High Dose TBS-2</title>
            <description>High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
High dose TBS-2: High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sexual Event Satisfaction Over a 28-day Period (Day 57 to Day 84) Compared to Baseline (Day -28 to Day 0)</title>
          <description>as measured by Monash Women's Health Program Female Sexual Satisfaction Questionnaire (MONASH WHP FSSQ) question 11.
MONASH WHP FSSQ question 11 asks participants to comment on how satisfying they found the sex to be from &quot;Not at all&quot; to &quot;Very much so&quot;. The lowest score is 1 and the highest is 9. All scores for each 28-day period were averaged. Change from baseline was obtained by subtracting baseline 28-day average from the 28-day period at the end of the study (Day 57 to 84).</description>
          <population>The number of participants analyzed is equal to the number of participants who completed the Day 84 visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="1.624"/>
                    <measurement group_id="O2" value="1.52" spread="1.586"/>
                    <measurement group_id="O3" value="1.59" spread="1.803"/>
                    <measurement group_id="O4" value="1.27" spread="1.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Distress Due to Female Orgasmic Disorder From Day 0 Baseline to Day 84</title>
        <description>as measured by Female Sexual Distress Scale (FSDS-DAO) Question #15 on Day 0 and 84, respectively. Question #15 evaluates the level of distress related to problems with orgasm. It is rated on a 5-point Likert scale (from 0 to 4, i.e. never [0], rarely [1], occasionally [2], frequently [3], or always [4]). Higher scores indicate more distress.</description>
        <time_frame>Day 0 and Day 84</time_frame>
        <population>The number of participants analyzed is equal to the number of participants who completed the Day 84 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
Placebo: placebo intranasal gel administered prn, 2-8 hours before a planned sexual event</description>
          </group>
          <group group_id="O2">
            <title>Low Dose TBS-2</title>
            <description>Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
Low dose TBS-2: Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
          </group>
          <group group_id="O3">
            <title>Medium Dose TBS-2</title>
            <description>Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
Medium dose TBS-2: Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
          </group>
          <group group_id="O4">
            <title>High Dose TBS-2</title>
            <description>High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
High dose TBS-2: High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Distress Due to Female Orgasmic Disorder From Day 0 Baseline to Day 84</title>
          <description>as measured by Female Sexual Distress Scale (FSDS-DAO) Question #15 on Day 0 and 84, respectively. Question #15 evaluates the level of distress related to problems with orgasm. It is rated on a 5-point Likert scale (from 0 to 4, i.e. never [0], rarely [1], occasionally [2], frequently [3], or always [4]). Higher scores indicate more distress.</description>
          <population>The number of participants analyzed is equal to the number of participants who completed the Day 84 visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.09"/>
                    <measurement group_id="O2" value="-1.3" spread="1.40"/>
                    <measurement group_id="O3" value="-0.9" spread="1.10"/>
                    <measurement group_id="O4" value="-0.8" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Global Sexual Functioning From Day 0 to Day 84</title>
        <description>as measured by Female Sexual Function Index (FSFI) on Day 0 and 84, respectively. The FSFI, a 19-item questionnaire, has been developed as a brief, multidimensional self-report instrument for assessing the key dimensions of sexual frustration in women. The questionnaire provides scores on 6 domains of sexual function (desire, arousal, lubrication, orgasm, satisfaction, and pain) as well as a total score. Fifteen items are rated on a 6-point Likert scale (from 0 to 5) and 4 items on a 5-point Likert scale (from 1 to 5). The scores are added and converted using a conversion factor so that the maximum score for each domain is 6. The overall FSFI score can range from 2 to 36. Higher scores indicate better or higher sexual function.</description>
        <time_frame>Day 0 and Day 84</time_frame>
        <population>The number of participants analyzed is equal to the number of participants who completed the Day 84 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
Placebo: placebo intranasal gel administered prn, 2-8 hours before a planned sexual event</description>
          </group>
          <group group_id="O2">
            <title>Low Dose TBS-2</title>
            <description>Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
Low dose TBS-2: Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
          </group>
          <group group_id="O3">
            <title>Medium Dose TBS-2</title>
            <description>Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
Medium dose TBS-2: Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
          </group>
          <group group_id="O4">
            <title>High Dose TBS-2</title>
            <description>High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
High dose TBS-2: High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Global Sexual Functioning From Day 0 to Day 84</title>
          <description>as measured by Female Sexual Function Index (FSFI) on Day 0 and 84, respectively. The FSFI, a 19-item questionnaire, has been developed as a brief, multidimensional self-report instrument for assessing the key dimensions of sexual frustration in women. The questionnaire provides scores on 6 domains of sexual function (desire, arousal, lubrication, orgasm, satisfaction, and pain) as well as a total score. Fifteen items are rated on a 6-point Likert scale (from 0 to 5) and 4 items on a 5-point Likert scale (from 1 to 5). The scores are added and converted using a conversion factor so that the maximum score for each domain is 6. The overall FSFI score can range from 2 to 36. Higher scores indicate better or higher sexual function.</description>
          <population>The number of participants analyzed is equal to the number of participants who completed the Day 84 visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" spread="5.622"/>
                    <measurement group_id="O2" value="3.42" spread="6.278"/>
                    <measurement group_id="O3" value="3.33" spread="6.707"/>
                    <measurement group_id="O4" value="3.35" spread="5.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>84 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
Placebo: placebo intranasal gel administered prn, 2-8 hours before a planned sexual event</description>
        </group>
        <group group_id="E2">
          <title>Low Dose TBS-2</title>
          <description>Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
Low dose TBS-2: Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
        </group>
        <group group_id="E3">
          <title>Medium Dose TBS-2</title>
          <description>Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
Medium dose TBS-2: Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
        </group>
        <group group_id="E4">
          <title>High Dose TBS-2</title>
          <description>High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
High dose TBS-2: High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urine Analysis Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Inflamation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Nasal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Nasal Mucosal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hair Growth Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hirsutism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nathan Bryson, Chief Scientific Officer</name_or_title>
      <organization>Acerus Pharmaceuticals Corporation</organization>
      <phone>1-416-679-0776</phone>
      <email>nbryson@aceruspharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

